Leukemia News

In this video, Farhad Ravandi, MD, reviews recent advances in acute myeloid leukemia therapies discussed at the Society of Hematologic Oncology Annual Meeting.

ASH will honor Donna S. Neuberg, ScD, with the 2021 Exemplary Service Award at this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

Demographic reporting requirements established more than a decade ago to improve diversity in acute leukemia clinical trials did not appear to result in greater enrollment of Black and Hispanic patients, according to a study in Blood Advances.

The FDA approved brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile.

September is Blood Cancer Awareness Month.

The completion of cancer-directed therapy is a time for celebration.

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.